London: GlaxoSmithKline PLC’s cervical cancer vaccine ‘Cervarix’ has received nod for sale across the European Union.

The vaccine has been sanctioned to avert pre-cancerous wounds and cervical cancer caused by human papillomavirus types 16 and 18 that held responsible for over 70 per cent of all cervical cancer cases.

The world’s second-biggest drug manufacturer said that the indication for Cervarix is based on statistics developed by clinical studies in girls and young women between 10 and 25.

The authorization follows a commendation by a European Medicines Agency board of specialists in July.